Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Roche’s enicepatide delivers 15.5% weight loss in type 2 diabetes Phase II trial
The once-weekly GLP-1 and GIP medicine also brought blood sugar into the normal range for 62% of patients at its highest dose, supporting plans for broader Phase III development in 2027.
GSK expands blood-cancer pipeline with Chimagen T-cell engager deal worth up to $750m
GSK is acquiring global rights to a preclinical trispecific T-cell engager from Chimagen Biosciences, with a first human study planned for 2027. The programme deepens the companies’ relationship and gives GSK another route into a multiple-myeloma market where efficacy, durability and tolerability still leave room for improvement.
Handa Pharmaceuticals wins final FDA approval for OMCAZIO as $2.1bn Cabometyx market faces new rival
Handa Pharmaceuticals has secured final FDA approval for OMCAZIO, a cabozantinib formulation that can be taken with or without food, opening U.S. competition around Exelixis’ multibillion-dollar franchise.
FDA approves Eli Lilly’s Inluriyo-Verzenio combination for ESR1-mutated breast cancer
The United States Food and Drug Administration has approved Inluriyo with Verzenio for a genetically defined form of advanced breast cancer after endocrine therapy. In a 159-patient analysis, median progression-free survival reached 11.1 months with the combination versus 5.5 months with Inluriyo alone, expanding Eli Lilly's ability to pair two medicines from its own oncology portfolio.
Retatrutide development: Phase 3 results, 2027 FDA filing, TRIUMPH trials and what comes next
Eli Lilly and Company’s retatrutide programme has completed the core Phase 3 clinical package supporting planned submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea. The investigational triple hormone receptor agonist is moving toward a U.S. filing in the first quarter of 2027 while additional studies test diabetes, cardiovascular and kidney outcomes, liver disease, chronic pain, maintenance treatment and its performance against tirzepatide.
Pharming expands Joenja into children as rare-disease growth offsets RUCONEST pressure
Pharming has secured FDA approval for Joenja in children aged four to 11 weighing at least 27 kg, widening a rare-disease franchise whose quarterly revenue grew 40% while RUCONEST declined.
Dr. Reddy’s lands Qdenga distribution deal as India prepares first dengue vaccine launch
Dr. Reddy’s Laboratories will promote and distribute Takeda’s Qdenga dengue vaccine in India, creating a new commercial opportunity after regulators approved the country’s first dengue vaccine for people aged four to 60.
Avacta AVA6103 clears clinical mechanism hurdle as 2027 efficacy test moves into focus
Avacta Group’s first human AVA6103 data show controlled exatecan release and encouraging tolerability at doses above conventional exatecan’s published maximum tolerated level, strengthening the preCISION platform thesis while leaving clinical efficacy as the next decisive test.
Novartis drops ALS drug lifonebart after Phase 2 trial misses key goals
Novartis has discontinued development of VHB937, or lifonebart, in amyotrophic lateral sclerosis after a 251-patient Phase 2 trial missed its primary and secondary objectives, adding to several recent pipeline disappointments.
Novo Nordisk’s $1.4bn Orbis deal pushes obesity drug race deeper into oral medicines
Novo Nordisk has signed a discovery and licensing agreement worth up to $1.4 billion with Orbis Medicines to develop orally available macrocycle therapies for cardiometabolic disease, extending the Wegovy maker’s strategy beyond injectable GLP-1 drugs and its existing oral semaglutide technology.